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Defective vaccinia viruses were constructed that express functional Moloney murine leukemia virus-based vector
genomes, giving rise to substantial titers of transduction-competent retrovirus particles after infection of a retroviral
packaging cell line. For this purpose, the proviral retrovirus genome, engineered into the vaccinia virus mutant, was subjected
to several modifications, including the replacement of retroviral promoter sequences by vaccinia virus sequences and the
precise fusion of the transcription stop signal downstream of and the removal of such signals within the transcription unit,
allowing cytoplasmic transcription of distinct full-length retroviral transcripts. Vaccinia-mediated expression of retroviral
vector particles could be observed as early as 3 h postinfection and resulted in stable transduction of NIH/3T3 target cells
at higher titers than the control performed by conventional plasmid transfections. Thus at least part of the vaccinia life cycle
and retroviral assembly can occur concomitantly. Due to the favorable properties of vaccinia vectors, including high coding
capacity, stability, and wide host range, defective vaccinia viral/retroviral chimeric vectors are promising tools for gene
therapy applications. © 1999 Academic Press
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Current viral vectors used in gene therapy include
efective retroviruses (for a review, see Boris-Lawrie
nd Temin, 1993; Miller, 1997) and defective adenovi-
uses (Li et al., 1993), including adenovirus minichro-
osomes (Hay et al., 1984; Kochanek et al., 1996) and
deno-associated viruses (for a review, see Berns and
iraud, 1995; Kremer and Perricaudet, 1995). Recently,
himeric virus or virus-derived systems have been
escribed as production and potential delivery vectors
or retroviruses. Semliki Forest virus-derived replica-
ion competent RNAs were electroporated into host
ells and used to produce recombinant retroviral par-
icles (Li and Garoff, 1996; Wahlfors et al., 1997). Fur-
hermore, herpesvirus amplicons expressing gag, pol,
nd env genes were shown to rescue defective lacZ
etrovirus in a cell line carrying a corresponding pro-
irus (Savard et al., 1997). In addition, an adenovirus/
etrovirus chimeric system has been described con-
isting of two adenoviruses: the first one encoding
etroviral packaging functions and the second one
ncoding a defective retroviral genome. If both viruses
oinfect one target cell, the system allows in vivo gene
ransduction (Feng et al., 1997). In this report, we
escribe the use of vaccinia virus, one of the most
idely used vectors in molecular and cell biology
1 To whom reprint requests should be addressed. Fax: *43-2212-
w716. E-mail: falknef@baxter.com.
107Moss, 1996; Paoletti, 1996), as a chimeric carrier for
mall RNA virus genomes. The development of uracil
NA glycosylase (UDG)-defective vaccinia viruses,
eplicating only in engineered complementing cell
ines (Holzer and Falkner, 1997), has allowed us to
nvestigate defective vaccinia as a chimeric carrier for
etroviral genomes. We describe UDG-deficient vac-
inia virus, carrying a modified defective provirus that,
n transcription in the cytoplasm of retroviral packag-
ng cells, induces significant titers of transducing de-
ective retroviral particles.
RESULTS
utline of the experimental approach
Vaccinia virus transcribes its genes, replicates its
NA, and assembles its virions in the cytoplasm. Retro-
irus genomes, on the other hand, are transcribed from
uclear proviruses, further modified in the nucleus, pack-
ged into virions at the cellular membrane, and finally
eleased by budding (for a review, see Coffin, 1996). For
he construction of a chimeric poxviral/retroviral vector, it
as therefore of interest to evaluate the hypothesis that
t least part of the complex life cycles of both viruses can
ccur concomitantly in the same cell. To test these as-
umptions, a defective proviral genome was modified to
erve as an efficient vaccinia virus early transcription
nit and inserted into a defective vaccinia virus, which
as used to infect a retroviral packaging cell line. Su-
0042-6822/99 $30.00
Copyright © 1999 by Academic Press
All rights of reproduction in any form reserved.
p
d
M
d
s
e
(
l
p
m
u
t
(
p
w
f
t
(
r
n
I
v
g
t
v
n
u
s
n
C
d
l
1
t
M
i
p
U
A
e
t
c
s
s
t
s
s
f
t
p
r
108 HOLZER ET AL.ernatants of the infected cells were then used to trans-
uce NIH/3T3 cells. The approach is depicted in Fig. 1.
odification of the retroviral transcription unit
Vaccinia virus early transcripts are capped mRNAs of
iscrete length terminating ;50 bp downstream of a
pecific termination signal (Yuen and Moss, 1987). Thus
arly genes usually carry no termination signal
TTTTTNT) within the coding region but in the 39 untrans-
ated region. To convert the defective proviral DNA
resent in the plasmid pLXSN (Fig. 2A) (Miller and Ros-
an, 1989) into a functioning vaccinia early transcription
nit, three internal TTTTTNT signals were removed, and
he provirus was cloned into the vector pTKgpt-selP
Pfleiderer et al., 1995), linking it to a strong early–late
romoter (Chakrabarti et al., 1997). The resulting plasmid
as designated pTKgpt-LXSN. The structure of the de-
ective provirus present in pLXSN is outlined in Fig. 2A;
he proviral genome consists of the long terminal repeats
LTRs) with their characteristic repeat (R) and unique (U)
egions, the packaging signal C, and an SV40 promoter-
eomycin (neo) gene cassette (Miller and Rosman, 1989).
n the plasmid pTKgpt-LXSN and the corresponding virus
FIG. 1. Schematic representation of the poxviral/retroviral vector
ystem. Packaging cells infected with defective chimeric vaccinia virus
ynthesize retroviral transcripts in the cytoplasm that are packaged into
unctional retrovirus vector particles. On infection of target cells by
hese particles, reverse transcription and stable integration of the
rovirus result in transduction of the expression cassette into the
ecipient cell.d-LXSN (see below), the U3 and downstream U5 re- rions have been deleted from the provirus. The residual
ranscription unit has been placed under the control of a
accinia virus promoter and is flanked by thymidine ki-
ase (tk) gene sequences; vaccinia transcription starts
pstream of the 59-repeat (R) and stops at a TTTTTNT
ignal inserted downstream of the polyadenylation sig-
al of the retroviral transcription unit (Fig. 2B).
onstruction and genomic characterization of the
efective virus vd-LXSN
The plasmid pTKgpt-LXSN was inserted into the tk
ocus of the defective vaccinia virus eVAC-1 (Holzer et al.,
998), and recombinants were plaque purified several
imes in the complementing cell line RK-D4R-44 (see
aterials and Methods), finally resulting in the virus
FIG. 2. Schematic representation of the retroviral transcription units
n plasmid and virus constructs. (A) Transcription from the pLXSN
roviral vector takes place in the nucleus and is driven by the retroviral
3 or the internal SV40 promoter (open arrows). The processing signal
ATAAA (vertical arrow) defines the 39-end of the message, whereas
lements with the sequence TTTTTNT (*) are ignored by the nuclear
ranscription apparatus. (B) A vaccinia virus promoter (filled arrow)
ontrols transcription, and TTTTTNT motifs, acting as early viral tran-
cription termination signals, have been removed from the vector
equence. Transcription is terminated at such a signal downstream of
he 39-R region, resulting in a message that is recognized as genomic
etroviral RNA (C) and packaged into nascent virions.
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109POXVIRAL/RETROVIRAL VECTORS, GENE THERAPYd-LXSN. In the genome of this defective virus, the pro-
iral transcription unit contains the two retroviral “R”-
egions (Fig. 2B); these repeats, although small in size
;50 bp), might destabilize the genetic construct and
ead to the loss of the insert. To evaluate the stability and
xclude potential contamination by parental virus, viral
NAs were prepared, cleaved with appropriate restric-
ion enzymes, and subjected to Southern blotting using
eo- and tk-specific probes. The bands predicted for
d-LXSN were found; no tk wild-type gene was detect-
ble, and no evidence for instability was noted, confirm-
ng the identity and purity of the construct (data not
hown). In addition, replicating virus was not detectable
n the defective vaccinia stocks using a sensitive assay
rotocol (detection limit, one replicating in 4 3 107 de-
ective viruses; see Holzer et al., 1998).
ull-length retroviral transcripts are produced in cells
nfected with the chimeric virus
Due to the deletion of the UDG gene, the virus vd-
XSN abortively infects its host cells, transcribes exclu-
ively early genes, and produces only early proteins. To
heck the properties of vd-LXSN in this respect, nonper-
issive RK13 cells and complementing RK-D4R-44 cells
ere infected with the virus, and total RNAs were pre-
ared, glyoxylated, and subjected to Northern blotting.
s a positive control, retroviral producer cell lines were
stablished by transfecting the plasmid pLXSN into the
ackaging cell line PT67 (Fig. 3). In both the producer cell
ines (lanes 1–3) and the vd-LXSN-infected cells (lanes
FIG. 3. Northern blot of vaccinia-transcribed retroviral genomes.
K13 cells and the complementing cell line RK-D4R-44 were infected
ith wild-type or recombinant vaccinia virus as indicated at an m.o.i. of
0 pfu/cell. Total RNA was isolated at 2 or 8 h p.i., whereas RNA of
etroviral producer cell lines (lanes 1–3) was isolated when the mono-
ayers reached confluency. The blot was probed with neo antisense
ranscripts. Fragment sizes of the RNA marker are given in kilobases,
nd the expected retroviral genomic transcript is indicated by an arrow.0 and 11), the full-length transcript of the retroviral aenome was detectable by a neomycin-specific probe
arrow). In addition, a transcript most probably initiated
y the internal SV40 promoter is visible as a 1.4-kb band
n the producer lines (lanes 1–3), whereas only a faint
and is detectable, with the vaccinia-induced RNA being
ynthesized solely by the viral transcription machinery in
he cytoplasm of the host cell. This weak band migrates
ust below the 18S ribosomal RNA band and is probably
n artifact produced by compression of RNA, resulting in
higher local hybridization background. Because the
irus has a prolonged early phase, the transcripts were
hecked after 2 and 8 h of infection and accumulation
as noted (compare lanes 10 and 11). Late viral RNA
repared from complementing cells showed the typical
accinia late smear, consisting of heterogeneously sized
ranscripts (lane 12). The transcriptional analysis con-
irmed the expected properties of the vaccinia-incorpo-
ated proviral transcription unit.
ransduction-competent retroviral particles are
roduced in a retroviral packaging cell line
To demonstrate that the cytoplasmically transcribed
etroviral genomes are packaged and form transducing
etroviral particles, colony-forming assays were per-
ormed with cell culture supernatants from vaccinia-in-
ected packaging cells. The supernatants were filtered
hrough 0.45-mm filters to remove large particles and
lated onto NIH/3T3 indicator cells, which were then
ubjected to G418 selection. As a positive control, the
ndicator cells were transduced by particles obtained
FIG. 4. Colony-forming assay in NIH/3T3 cells with vaccinia-induced
etroviral particles. Dishes with subconfluent PT67 packaging cells (106
ells) were infected with the vaccinia viruses vd-LXSN (A) or vdR-XSN
B) at an m.o.i. of 1.0 pfu/cell or transfected with 15 mg of pTKgpt-LXSN
C) or pLXSN (D) plasmid DNA. At 8 h after vaccinia virus infection and
8 h after plasmid transfection, respectively, serial dilutions of the
upernatants were used to transduce NIH/3T3 cells; 1:100 dilutions of
typical experiment are shown.
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110 HOLZER ET AL.fter transfection of the packaging cell line with the
lasmid pLXSN (Fig. 4D). In the negative control, the
lasmid pLXSN was substituted by the vaccinia insertion
lasmid pTKgpt-LXSN (Fig. 4C). In the crucial experi-
ent, the packaging cell line PT67 was infected with the
irus vd-LXSN, and cell culture supernatants were sub-
ected to the colony-forming assay. Surprisingly, the pox-
iral/retroviral chimeric virus induced the production of
ransducing retroviral particles, detectable by their ability
o give rise to G418-resistant NIH/3T3 cells in the colony
ssay (Fig. 4A). Use of an improved chimeric virus (vdR-
SN; see below) even resulted in significantly elevated
iters (Fig. 4B). Colony-forming assays, performed with
ell culture supernatants obtained after transfection of
he packaging cell line with the vaccinia insertion plas-
id pTKgpt-LXSN, did not yield transducing colonies
ecause in this construct, the proviral promoter region
ocated in the U3 region of the LTR is substituted by a
accinia promoter (see Fig. 2), which is not active in the
uclear context. In addition, transcripts originating from
he SV40–neo gene cassette lack the retroviral packag-
ng signal and are not usually packaged into particles;
ven if this were the case, the lack of the 59 LTR se-
uences in potential SV40–neo transcripts would prevent
everse transcription and transduction. Therefore, in con-
rast to the use of nuclear DNA viruses as retroviral
arriers, neo-positive colonies result only from retroviral
ransduction events.
mprovement of the system by precise promoter
usion
The titers of transducing retroviral particles obtained
n the prototype vector vd-LXSN were low (see below). A
loser inspection of the molecular structure of retroviral
enome in vd-LXSN revealed that the fusion of the RNA
nitiation site of the vaccinia early promoter with the 59
FIG. 5. Sequences around the RNA start sites of the different con-
tructs. Transcription start sites in the Moloney murine leukemia virus
MoMLV) provirus (A) and in two different vaccinia/retrovirus chimeras
B and C) are indicated by arrows. Boxes mark the first nucleotides of
he regular retroviral transcript, starting with the R region. The critical
arly promoter motifs in the vaccinia constructs are underlined. The
onretroviral sequence of the transcript in vd-LXSN (B) is indicated in
old.nd of the retroviral genome was suboptimal (Fig. 5). A pew plasmid and an improved virus therefore were con-
tructed, designated pR-XSN and vdR-XSN, respectively;
n both, the vaccinia promoter and retrovirus insert are
ptimally fused (Fig. 5C). In the previous construct (vd-
XSN), transcription starts at a G residue ;20 bases
pstream of the proviral R region (Fig. 5B). Because
riming of reverse transcription is mediated by the R
egion, the extra 20 bases do not base pair and should
esult in inefficient reverse transcription. Therefore, in
he improved construct, a synthetic early promoter motif
as placed such that transcription starts precisely at the
eginning of the R region (Fig. 5C), as confirmed by
rimer extension experiments (data not shown). The vi-
us vdR-XSN induced the expected early genomic tran-
cripts in infected nonpermissive cells (Fig. 3, lanes 8
nd 9). Although the total amount of vector transcripts
as lower than that seen in vd-LXSN (lanes 10 and 11),
he improved construct vdR-XSN resulted in a retroviral
iter exceeding that obtained with vd-LXSN by ;2 logs
nd the transfected plasmid pLXSN by 1 log (see below,
nd Fig. 4), showing that the vaccinia system is an
fficient tool for the production of defective transduction-
ompetent retroviral particles (see also Fig. 4B). Al-
hough the titers in repeated experiments varied with the
ondition of the packaging and the target cells, the ratio
f the titers outlined above remained relatively constant.
he vaccinia-induced retroviral particles integrate into
he host genome
Several transduced G418-resistant NIH/3T3 cell
lones, obtained from the chimeric poxvirus/retrovirus
ystem (the vdR-XSN/PT67 cell culture supernatants),
ere grown to larger cultures, and high-molecular-
eight genomic DNA was isolated. The DNAs were
leaved with the restriction enzymes Asp718 and EcoRI,
ubjected to a Southern blot analysis, and hybridized
ith a neomycin-specific probe. The enzyme Asp718
leaves in the R regions (see also Fig. 2) resulting in an
nternal fragment of 2.8 kb (Fig. 6A, arrow) common to
roviral transcription units independent of the integration
ite in the target cell. This common 2.8-kb fragment was
isible in the DNAs originating from the plasmid control
R-XSN (Fig. 6A, lane 1) and in the transduced cell lines
lanes 4 and 5). No neo-specific fragments were detect-
ble in the negative control (lane 3).
As predicted, the fragments produced by EcoRI cleav-
ge varied in the different transduced cell clones (Fig.
B, lanes 4 and 5) because EcoRI is present only once in
he provirus. EcoRI cleaves in the middle of the neo gene
assette, resulting in two hybridizing fragments. Each
ransduced cell clone displayed individually hybridizing
ragments, confirming random integration. The analysis
onfirmed the results of the colony-forming assays; the
oxviral/retroviral vectors produce transduction-compe-
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111POXVIRAL/RETROVIRAL VECTORS, GENE THERAPYent retroviral particles, and the provirus stably integrates
nto the hosts genome and is detectable in repeatedly
assaged cell clones.
ptimal production of retroviral particles occurs
ithin the first 8 h of infection
To determine the optimal conditions for the production
f retroviral particles, the roles of multiplicity of infection
m.o.i.) and of incubation time in production rates were
etermined. The optimal infection dose with the im-
roved poxviral/retroviral vector was determined by in-
ecting the packaging cell line PT67 with increasing
mounts of vdR-XSN and titrating the supernatants on
IH/3T3 cells in the presence of G418. As shown in Fig.
A, transduction rates correlated with the vaccinia doses
t a low m.o.i., whereas elevation of the m.o.i. over 1
laque-forming unit per cell led to only a modest raise in
etroviral titers. The optimal incubation time was deter-
ined by infecting the packaging cells with the improved
ector vdR-XSN at an m.o.i. of 0.5 and titering the super-
atants at the indicated time points (Fig. 7B). To compare
he system with conventional protocols, pLXSN DNA was
ransfected into packaging cells, and supernatants were
itered after 48 h. With 8 3 102 cfu/ml, the transfection-
nduced titer did not reach the peak values of vaccinia-
nduced supernatants, whereas the cloned producer line
FIG. 6. Southern blots of total DNAs prepared from neo-positive cell
lones. High-molecular-weight DNA was extracted from wild-type NIH/
T3 cells (lanes 3) and from NIH/3T3 clones transduced with vdR-XSN-
nduced retroviral particles (lanes 4 and 5). For the positive controls, 30
g of NIH/3T3 DNA was spiked with 10 pg of the plasmid pR-XSN
igested with Asp718 (A) or EcoRI (E) (lanes 1 and 2). As a negative
ontrol, pure NIH/3T3 cell DNA is shown in lanes 3. The cellular DNAs
ere digested with Asp718 (A) or EcoRI (B). The blots were probed with
SV2-neo plasmid-DNA.0 (see also Fig. 3) resulted in significantly higher titers i4 3 105 cfu/ml). More surprisingly, retroviral vector par-
icles could be harvested as early as 3 h postinfection
p.i.), reaching maximal titers at an incubation time be-
ween 6 and 9 h (5 3 104 cfu/ml), indicating that pack-
ging, assembly, and release of the defective retrovi-
uses are rapid processes.
DISCUSSION
Because retroviral vectors cannot be grown to high
iters, tend to be unstable, and are sensitive to lysis by
omplement when transfused into patients, more robust
etroviral delivery systems are highly desirable. In a
revious report, defective adenovirus/retrovirus chime-
as were constructed, which allowed in vivo retroviral
ransduction by coinfection of a host cell with two recom-
inant adenoviruses: one expressing the retroviral ge-
ome and the other one expressing the packaging func-
ions (Feng et al., 1997). In situ transduction of neighbor-
ng cells in an animal could be demonstrated after
mplantation of doubly infected tumor cells into nude
ice. This report showed that chimeric large DNA vi-
uses could induce the production of retroviral particles
n situ (Feng et al., 1997). A more elegant approach would
e the direct use of one large carrier virus obviating the
FIG. 7. Dose dependence and kinetics of vaccinia virus-induced
etrovirus production. (A) PT67 packaging cells (106 cells) were infected
ith the vaccinia recombinant vdR-XSN using increasing amounts of
irus (pfu/cell). Supernatants were harvested 6 h p.i., and retroviral
iters, given in cfu/ml, were determined in focus assays. (B) vdR-XSN
nfections were done as above at an m.o.i. of 0.5 pfu/cell, and from a
otal of 5 ml, 200-ml aliquots of supernatant were removed at the times
ndicated and titrated in focus assays.
n
p
v
1
d
g
a
b
f
o
i
b
b
H
n
b
t
n
s
o
i
f
c
t
c
a
n
p
c
e
e
c
f
i
o
d
n
d
e
c
R
n
c
o
d
n
t
a
w
t
p
t
p
p
t
r
o
g
r
r
v
c
e
r
t
r
o
c
v
t
a
V
C
t
R
o
P
I
v
C
s
a
c
P
i
I
T
G
p
G
A
A
o
a
T
s
A
1
112 HOLZER ET AL.eed for double infections and implantations. This ap-
roach is currently not feasible with classic adenovirus
ectors due to the limited packaging capacity (Bett et al.,
993).
An ideal system for this purpose, however, may be
efective vaccinia viruses expressing exclusively early
enes. Due to the large coding capacity of up to 50 kb
nd multiple potential insertion sites, it should be feasi-
le to construct vaccinia viruses expressing packaging
unctions and provirus in one vector. With the goal of
btaining subunit and/or live vaccines, human or simian
mmunodeficiency virus gag, pol, and env genes have
een expressed in vaccinia, and particle formation has
een demonstrated (see, for example, Haffar et al., 1990;
irsch et al., 1996; Karacostas et al., 1989). Our findings
ow show that modified retroviral genomes, transcribed
y vaccinia, can be packaged in packaging cell lines into
ransduction-competent defective retrovirus. Potential
egative effects of the vaccinia infection on the synthe-
is, assembly, and release of retroviral particles were not
bserved. A chimeric vaccinia virus expressing packag-
ng functions and the defective provirus will therefore be
easible and may allow in vivo retroviral transduction of
ells. Moreover, due to the cytoplasmic site of transcrip-
ion, it should be feasible to construct particularly effi-
ient retroviral transduction units. Vaccinia, in contrast to
denovirus or herpesvirus, recognizes neither splicing
or nuclear polyadenylation (pA) signals. Plasmid ex-
ression vectors used to produce proteins in vertebrate
ells usually contain introns in their transcription units to
nhance expression levels; in particular, the efficient
xpression of human clotting factor VIII requires intron-
ontaining gene cassettes (Chuah et al., 1995). There-
ore, a vaccinia-produced retroviral genome containing
ntrons and internal pA signals should allow transduction
f optimal transcription units. Internal pA signals, in ad-
ition, prevent transcription of full-length retroviral ge-
omes in the nucleus, adding to the safety of the trans-
uced gene cassette.
Defective vaccinia vectors expressing exclusively
arly genes, as opposed to other (non)replicating vac-
inia vectors, are particularly suited as carriers for small
NA viruses, not only for safety reasons because they do
ot replicate in natural hosts but also because only
orrectly processed and dimerized retroviral RNA, as
btained by early transcription, forms functional trans-
ucing particles. Vaccinia late transcripts are heteroge-
eous in size; late RNAs with the correct size and con-
aining a packaging motif may be packaged but presum-
bly give rise to large amounts of pseudoparticles.
With the prototype virus vd-LXSN, the titers obtained
ere low. On precise fusion of the RNA initiation site of
he vaccinia promoter with the first nucleotide of the
roviral R region, a ;100-fold increase in the transducingiter was achieved, confirming the requirement of precise sriming in the reverse transcription process. The RNA
rimer produced in the first step of the reverse transcrip-
ion process has, with the prototype virus-produced ret-
oviral genomes as a template, a noncomplementary
verhang that, when the primer jumps to the 39 end of the
enome, interferes with but obviously does not prevent
everse transcription. A similar effect was seen with
etroviral particles produced from Semliki Forest virus
ectors (Li and Garoff, 1996; Wahlfors et al., 1997). In
onclusion, defective vaccinia vectors induce a relatively
fficient production of transduction-competent defective
etroviral particles in retroviral packaging cell lines. At
he ideal m.o.i. of 1.0 and an incubation time of 8 h, the
etroviral titer induced by vaccinia virus exceeded that
btained by the conventional plasmid transfection proto-
ol by ;1 log. The next step in developing an in vivo
accinia-based transduction system will be insertion of
he retroviral packaging functions into the vaccinia vector
lready transcribing the retroviral genome.
MATERIALS AND METHODS
irus and cell lines
The African Green Monkey kidney cell line CV-1 (ATCC
CL-70), the rabbit kidney cell line RK13 (ATCC CCL-37),
he NIH/3T3 cell line (ATCC CRL-1658), and the Western
eserve (WR) strain of vaccinia virus (ATCC VR119) were
btained from American Type Culture Collection. The
T67 cell line was obtained from Clontech Laboratories,
nc. The cell line RK-D4R-44.20 has been described pre-
iously (Holzer and Falkner, 1997).
onstruction of plasmids
pCR-LX1-pCR-LX4. To substitute the three TTTTTNT
ignals in the proviral genome present in pLXSN (Miller
nd Rosman, 1989), a PCR-dependent mutagenesis pro-
edure was applied. Three fragments were amplified by
CR with the pLXSN template LX1-LX3 (1.6, 1.0, and 1.2 kb
n size) and subcloned into the pCRII vector (InVitrogen,
nc.). To construct pCR-LX1, the primers oRV-5 (59-TACG-
ACGGC GCGCCAGTCT TCCGATAG-39) and oRV-6 (59-
AACCGGTCG CCCCTGCGCT GAC-39) were used; for
CR-LX2, the primers oRV-7 (59-AGACGTCCCA GG-
ACTTTGG GGGCCGTATT TGTGGC-39) and oRV-8 (59-
GGCCGAGGC GGCCTCGGCC TCTGCATAAA TAAATA-
AAT TAG-39) were used; and for pCR-LX3, the primers
RV-9 (59-CGACCGGTTC TATTTGTCAA GACCGACCT-39)
nd oRV-10 (59-GCGGCCGCAA CTGCAAGAGG GTTTAT-
GGA-39) were used. The plasmid pCR-LX4 was con-
tructed by excising the fragment LX2 from pCR-LX2 with
atII and SfiI and inserting it into the plasmid pCR-LX1.
pTKgpt-LX3. The plasmid pTKgpt-selP (Pfleiderer et al.,
995), cleaved with NcoI and NotI, was ligated with the
mall 0.8-kb NcoI–NotI fragment isolated from pCR-LX3,
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113POXVIRAL/RETROVIRAL VECTORS, GENE THERAPYesulting in pTKgpt-LX3. This plasmid carries the correct
9 part of the proviral genome.
pLXSNmut. To modify a TTTTTNT signal in the neo
RF of pLXSN, a mutagenesis with the primers oRV35
59-AAATAGAACC GGTCGCCCCT GCGCTGAC-39) and
RV-9 (59-CGACCGGTTC TATTTGTCAA GACCGACCT-39)
sing the Quickchange mutagenesis kit (Stratagene,
nc.) was performed, resulting in a new PinAI site in the
lasmid pLXSNmut.
pCR-LX41. Substitution of the unique SfiI–SacI frag-
ent of pCR-LX4 with the modified 1.4-kb SfiI–SacI neo
assette from pLXSNmut resulted in the plasmid pCR-
X41; this plasmid contains the fully assembled modi-
ied provirus except for the extreme 39 end.
pTKgpt-LXSN. Insertion of the 2.7-kb SnaBI–SacI frag-
ent into the StuI–SacI cleaved plasmid pTKgpt-LX3
esulted in pTKgpt-LXSN.
pR-XSN. The plasmid pTKgpt-LXSN was digested with
deI and BbsI, thereby excising the early–late vaccinia
romoter upstream of the retroviral transcription unit.
igation with the oligonucleotides oPR1 (59-TATG-
AAAAA TTGAAATACT AGTGAATCCT ATT-39) and oPR2
59-GCGCAATAGG ATTCACTAGT ATTTCAATTT TTGCA-
9) resulted in the plasmid pR-XSN, in which an opti-
ized early vaccinia virus promoter signal is fused to the
etroviral R region.
onstruction of the viruses vd-LXSN and vd-RXSN
To construct the defective viruses vd-LXSN and vd-
XSN, the plasmids pTKgpt-LXSN or pTKgpt-RXSN, re-
pectively, were transfected into RK-D4R-44 cells before
nfection with the defective virus eVAC-1 (Holzer et al.,
998). Plaque assays were done under gpt selection
Falkner and Moss, 1988) in the RK-D4R-44 cell line.
olony-forming assay
NIH/3T3 cells were infected with retroviral particles
ssentially as described in the user manual of the Ret-
oXpress System (K1060–1; Clontech, Inc.). Selection
as performed with 500 mg/ml G418 (Sigma Inc.). Colo-
ies were stained with crystal violet after 10 days.
stablishment of retroviral producer cell lines
PT67 cells (Clontech, Inc.) were transfected with the
lasmid pLXSN (Graham and van der Eb, 1973), and
418-resistant colonies were isolated according to stan-
ard cell culture procedures.
orthern blots
Total RNA (20 mg) was glyoxylated, resolved on a 1%
garose gel, and blotted onto a nylon membrane (Hy-
ond N; Amersham Inc.). The blot was probed with an-isense RNA specific for the complete SV40 promoter
nd the neo gene.
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